

Assessment of Shoulder Pain in Rheumatoid Arthritis Patients by using High Resolution Musculoskeletal Ultrasound

Thesis

Submitted for Partial Fulfillment of Master Degree in Rheumatology

By

Najie Mohamed Samir Dahi M.B.B.Ch

Supervised By

Prof. Dr. Mervat Mamdouh Abogabal

Professor of Internal Medicine and Rheumatology Faculty of Medicine-Ain Shams University

Dr. Noran Osama El Azizi

Assistant Professor of Internal Medicine and Rheumatology Faculty of Medicine-Ain Shams University

Dr. Maha Ahmed El Serwe

Lecturer of Internal Medicine and Rheumatology Faculty of Medicine-Ain Shams University

Faculty of Medicine - Ain Shams University
2019



سورة البقرة الآية: ٣٢

Acknowledgments

First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.

I wish to express my deepest thanks, gratitude and appreciation to **Prof. Dr. Mervat Mamdouh**Abogabal, Professor of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, for her meticulous supervision, kind guidance, valuable instructions and generous help.

Special thanks are due to **Dr. Moran Osama El**Azizi, Assistant Professor of Internal Medicine and
Rheumatology, Faculty of Medicine, Ain Shams
University, for her sincere efforts, fruitful encouragement.

I am deeply thankful to **Dr. Maha Ahmed El**Serwe, Lecturer of Internal Medicine and Rheumatology,
Faculty of Medicine, Ain Shams University, for her great
help, outstanding support, active participation and
guidance.

Najie Mohamed Samir Dahi

Tist of Contents

| Title | Page No. |
|------------------------|----------|
| List of Tables | 5 |
| List of Figures | 10 |
| List of Abbreviations | |
| Introduction | 1- |
| Aim of the Work | |
| Review of Literature | |
| Rheumatoid Arthritis | |
| Shoulder Pain | 97 |
| Subjects and Methods | 115 |
| Results | 122 |
| Discussion | 173 |
| Summary and Conclusion | 180 |
| Recommendations | 183 |
| References | |
| Arabic Summary | |

List of Tables

| Table No. | Title | Page No. |
|--------------------|--|--------------------|
| Table (1): | Predictors of future development rheumatoid arthritis in patient recent onset arthritis | ts with |
| Table (2): | Criteria for the classification of rhe arthritis | |
| Table (3): | The 2010 American Colle Rheumatology/ European League Rheumatism classification crite rheumatoid arthritis | against ria for |
| Table (4): | Laboratory and Imaging I Associated | |
| Table (5): | RA Disease Activity Index | 72 |
| Table (6): | Differential Diagnosis of Rhe Arthritis | |
| Table (7): | DMARDs in RA: | 83 |
| Table (8): | Recommendation for optimal lab monitoring interval in patients v receiving DMARDs: | vith RA |
| Table (9): | TNF-α blocking agents | 87 |
| Table (10): | Agents and doses: | |
| Table (11): | Treatment recommendations for patients with high-risk comorbidities | |
| Table (12): | Causes of shoulder pain | 103 |
| Table (13): | Summary of clinical scenarios as mainly positive recommendations | • |
| Table (14): | Display of demographic characteris shoulder pain duration among (50) and (30) controls | patients |
| Table (15): | Display of rheumatoid arthritis variables among (50) patients | |

| Table No. | Title | Page No. |
|----------------------------|--|-------------|
| Table (16): Table (17): | Display of drug intake among (50 Display of laboratory data in (50 and (30) controls | D) patients |
| Table (18): | Display of frequency of painful painful (100) shoulders of (50) part | tients 128 |
| Table (19): | Display of frequency of non abnormal (100) shoulders of (50 according to US findings |)) patients |
| Table (20): | Display of X-ray findings among of patients and controls | |
| Table (21): | Display of abnormal US findings tendon and sheath by US am shoulders of (50) patients | nong (100) |
| Table (22): | Display of abnormal US finding scapularis tendon among (100) sh (50) patients. | noulders of |
| Table (23): | Display of abnormal US findings Spinatus tendon and muscle an shoulders of (50) patients | nong (100) |
| Table (24): | Display of abnormal US findings Spinatus tendon and muscle an shoulders of (50) patients | nong (100) |
| Table (25): | Display of abnormal US findings and Subcoracoid Bursae amoshoulders of (50) patients | ong (100) |
| Table (26): | Display of abnormal US finding acromion and sub-coracoid imamong (100) shoulders of (50) pat | pingement |
| Table (27): | Display of abnormal US fir humeral bone among (100)should patients | ndings in |

| Table No. | Title | Page No. |
|--------------------|--|---------------------|
| Table (28): | Display of abnormal US findings among (100) shoulders of (50) patier | |
| Table (29): | Display of abnormal US findings among (100) shoulders of (50) patier | |
| Table (30): | Comparison between patients and regarding age, sex, duration of spain and body mass index | shoulder |
| Table (31): | Comparison between shoulders of and controls as regard prese abnormal x-ray findings. | ence of |
| Table (32): | Comparison between shoulders of and controls as regard presence of abnormal US findings | f biceps |
| Table (33): | Comparison between shoulders of and controls as regard presence scapularis abnormal US findings | of sub- |
| Table (34): | Comparison between shoulders of and controls as regard presence of spinatus abnormal US findings | f supra- |
| Table (35): | Comparison between shoulders of and controls as regard presence of spinatus abnormal US findings | of infra- |
| Table (36): | Comparison between shoulders of and controls as regard presence of abnormal US findings | of bursa |
| Table (37): | Comparison between shoulders of and controls as regard prese impingement abnormal US findings | ence of |
| Table (38): | Comparison between shoulders of and controls as regard presence of hone abnormal US findings | patients numeral |

| Table No. | Title | Page No. |
|--------------------|---|--------------------|
| Table (39): | Comparison between shoulders of and controls as regard presence abnormal US findings | of ACJ |
| Table (40): | Comparison between shoulders of and controls as regard presence abnormal US findings | of GHJ |
| Table (41): | Comparison between DAS-28 subgregard age, BMI, disease duration duration and lab investigation | on, pain |
| Table (42): | Relation between biceps tendon and US abnormalities and disease (DAS-28 subgroups) | activity |
| Table (43): | Relation between sub-scapularis terabnormalities and disease activity subgroups). | (DAS-28 |
| Table (44): | Relation between supra-spinatus and muscle US abnormalities and activity (DAS-28 subgroups) | tendon disease |
| Table (45): | Relation between infra-spinatus and muscle US abnormalities and activity (DAS-28 subgroups) | tendon disease |
| Table (46): | Relation between SASD burs subcoracoid bursa US abnormalit disease activity (DAS-28 subgroups | sa and cies and |
| Table (47): | Relation between impingement abnormalities and disease activity subgroups). | nt US (DAS-28 |
| Table (48): | Relation between humeral bo abnormalities and disease activity subgroups). | ny US (DAS-28 |
| Table (49): | Relation between ACJ US abnor | rmalities |

| Table No. | Title | Page No. |
|--------------------|--|------------|
| Table (50): | Relation between GHJ US abno | |
| Table (51): | Relation between shoulder pain at tendon and sheath abnormalities in RA patients. | (by US) |
| Table (52): | Relation between shoulder pain scapularis tendon abnormalities (IRA patients | by US) in |
| Table (53): | Relation between shoulder pain as spinatus tendon and muscle abnot (by US) in RA patients | ormalities |
| Table (54): | Relation between shoulder pain a spinatus abnormalities (by US patients |) in RA |
| Table (55): | Relation between shoulder pain a abnormalities (by US) in RA patien | |
| Table (56): | Relation between shoulder primpingement abnormalities (by Upatients | (S) in RA |
| Table (57): | Relation between shoulder patients | JS) in RA |
| Table (58): | Relation between shoulder pain abnormalities (by US) in RA patien | and ACJ |
| Table (59): | Relation between shoulder pain abnormalities (by US) in RA patien | |
| Table (60): | Correlation between disease dura age, BMI, No. of tender and swoll VAS, DAS28, pain duration, and la | en joints, |

List of Figures

| Fig. No. | Title | Page No. |
|---------------------|---|-------------|
| Figure (1): | Adaptive and innate immune within the joint in RA | |
| Figure (2): | RA activity in MCP joints | |
| Figure (3): | Patient feet deformed by rh | |
| <u> </u> | arthritis | |
| Figure (4): | Ankle swelling in RA | 35 |
| Figure (5): | Cervical spines' deformities in RA | 37 |
| Figure (6): | Clinical organ system involve | ement of |
| | rheumatoid vasculitis | 39 |
| Figure (7): | Rheumatoid vasculitis leg ulcers | 39 |
| Figure (8): | Abnormalities of the shoulder in rh | neumatoid |
| | arthritis | 63 |
| Figure (9): | Rheumatoid arthritis of the ankle | 64 |
| Figure (10): | Rheumatoid arthritis of the hip join | t64 |
| Figure (11): | Rheumatoid arthritis of the cervical | spine65 |
| Figure (12): | US focal bone erosions in a patient | with ERA 67 |
| Figure (13): | MCP synovitis with power Doppler | signal68 |
| Figure (14): | | |
| | League Against Rheumatism | |
| | recommendations on rheumatoid | arthritis |
| | (RA) management | 85 |
| Figure (15): | Mechanism of action of TNFi and | non-TNFi |
| | biologics | |
| | Mechanism of Action of Tofacitinib. | |
| Figure (17): | Tuberculosis (TB) screening algo | |
| | biologics or tofacitinib | |
| • | Muscles and nerves of shoulder | |
| | Sex ratio among cases and controls. | |
| _ | Percent of patients with disease act | • |
| _ | Type of drugs taken by the RA patie | |
| Figure (22): | Frequency of painful and nor | _ |
| | shoulders of RA patients | 128 |

Tist of Figures cont...

| Fig. No. | Title | Page No. |
|---------------------|--|-----------|
| Figure (23): | X-ray findings among shoulders patients and controls | |
| Figure (24): | All US abnormalities which are locatrols than cases | nigher in |
| Figure (25): | All US abnormalities which are leases than controls. | nigher in |
| Figure (26): | Comparison between DAS28 score sas regard age, ESR and serum creat | ubgroups |
| Figure (27): | Significant US abnormalities patients with moderate versus seven | between |
| Figure (28): | activity | between |
| Figure (29): | shoulders | plains of |
| Figure (30): | 57 years old female RA patient con bilateral shoulder pain for 7 months | plains of |
| Figure (31): | 54 years old female RA patient con left shoulder pain for 2 weeks | plains of |
| Figure (32): | 38 years old female RA patient combilateral shoulder pain for 2 years | plains of |
| Figure (33): | 39 years old female RA patient con bilateral shoulder pain for 1 year | plains of |
| Figure (34): | 60 years old female RA patient combilateral shoulder pain for 1 year | plains of |
| Figure (35): | 53 years old female RA patient conright shoulder pain for 3 months | plains of |
| Figure (36): | 58 years old female RA patient con bilateral shoulder pain for 2 weeks | plains of |

Tist of Abbreviations

| Abb. | Full term |
|---------------|---|
| 4.07 | |
| | . Acromioclavicular joint |
| | . Anti-Citrullinated protein antibodies. |
| | . American College of Rheumatology |
| <i>ADAMTS</i> | . A disintegrin and metalloprotease with |
| | thrombospondin-1–like domains |
| <i>AICAR</i> | $. \ Aminoimidazo le \ carboxamide$ |
| | ribonucleotide |
| | . Alanine transaminase |
| | . Antinuclear antibody |
| | . Anti-cyclic citrullinated peptide antibodies |
| | . Anti-mutated citrullinated viment in |
| <i>APCs</i> | . Antigen presenting cells |
| <i>ARA</i> | . American Rheumatism Association |
| AST | . Aspartate transaminase |
| bDMARDs | $. \ Biological \ Disease \ modifying \ antirheum atic$ |
| | drugs |
| <i>BMI</i> | · · · · · · · · · · · · · · · · · · · |
| bsDMARDs | . Biosimilar Disease modifying |
| | antirheumatic drugs |
| <i>BUN</i> | . Blood urea nitrogen |
| <i>CBC</i> | . Complete blood count |
| <i>CDAI</i> | . Clinical Disease Activity Index |
| <i>CHD</i> | . Congestive heart failure |
| <i>COX</i> | |
| <i>CRP</i> | . C-reactive protein |
| csDMARDs | . Conventional synthetic Disease modifying |
| | antirheumatic drugs |
| <i>CT</i> | . Computed tomography |
| <i>CTS</i> | . Carpal tunnel syndrome |
| <i>DAMP</i> | . Damage-associated molecular pattern |
| DAS28 | . Disease Activity Score 28 joints |
| <i>DIP</i> | . Distal interphalangeal |
| DKK1 | . Dickkopf-1 |

Tist of Abbreviations cont...

| Abb. | Full term |
|-----------|--|
| DICARR | D. 1.0. |
| | Disease modifying antirheumatic drugs |
| | Evaluator global assessment |
| | Enzyme-linked immunosorbent assay |
| | European Medicines Agency |
| | Early Rheumatoid Arthritis |
| ES | |
| | Erythrocyte sedimentation rate |
| ESSR | European society of musculoskeletal |
| TIII AD | radiology |
| | European League Against Rheumatism |
| FcR | _ |
| | High-affinity IgE receptor |
| | Food and Drug Administration |
| | Fibroblast growth factor |
| | Fibroblast-like synoviocytes |
| | Global arthritis score |
| <i>GH</i> | |
| | Glenohumeral joint |
| GM-CSF | Granulocyte / macrophage colony- |
| TTA | stimulating factor |
| <i>HA</i> | · · · · · |
| | Health Assessment Questionnaire |
| ПАQ-D1 | Health Assessment Questionnaire Disability |
| 1100 | Index |
| | Hydroxychloroquine |
| | Human leukocyte antigen |
| | High resolution Computed tomography |
| | High resolution ultrasonography |
| | Heat-shock protein |
| • | Interferon-gamma Interferon gamma release assay |
| <i>IL</i> | , . |
| | Interteurin Interstitial Lung Disease |
| 1DD | Three stittut Dung Disease |

Tist of Abbreviations cont...

| Abb. | Full term |
|-------------|---|
| :NOC | In describe mitric and do counth stores |
| | Inducible nitric oxide synthetase |
| | Interphalangeal Interquartile range |
| <i>IV</i> | • |
| | Intravenous Janus kinase |
| | |
| | Joint space narrowing |
| <i>LEF</i> | |
| | Metacarpophalangeal |
| | Monocyte chemotactic protein-1 |
| | Matrix metallo-proteases |
| | Magnetic resonance imaging |
| | Musculoskeletal ultrasonography |
| | Metatarsophalangeal |
| | Methotrexate |
| NADPH | Nicotinamid adenine dinucleotide |
| NE D | phosphate-oxidase |
| | Nuclear factor kappa B |
| <i>NLR</i> | nucleotide-binding oligomerization |
| MO | domain–like receptor |
| <i>NO</i> | |
| No | |
| | Non-steroidal anti-inflammatory drugs |
| | Outcome measures in rheumatology |
| | Peptidylarginine deiminase |
| | Pathogen-associated molecular pattern |
| | Protease-activated receptor 2 |
| | Power Doppler |
| | platelet-derived growth factor |
| | Patient Global Assessment |
| | Prostaglandin H2 |
| <i>PICO</i> | Population, intervention, comparator, and |
| | outcomes |
| <i>PIP</i> | Proximal interphalangeal |

Tist of Abbreviations cont...

| Abb. | Full term |
|-----------------|--|
| DT | Ducth want him a time |
| PT | Quantitative standard monitoring of |
| QUEST-IA | nation to with phouse atoid anthritis |
| DΛ | patients with rheumatoid arthritis Rheumatoid arthritis |
| | |
| | Receptor activator of nuclear factor ?B |
| | ligand Red blood cells |
| RBCs | |
| <i>RF</i> | |
| <i>ROM</i> | |
| | Reactive oxygen species |
| | Subacromial-subdeltoid |
| SC | |
| SCr | |
| | Simplified Disease Activity Index |
| | Swollen joints count |
| | Systemic lupus erythematosus |
| | Statistical package for social science |
| <i>SSZ</i> | Sulfasalazine |
| <i>TB</i> | |
| TGF | Transforming growth factor |
| TGF - β | Transforming growth factor-beta |
| <i>Th</i> | T-helper cell |
| <i>TJC</i> | Tender joints count |
| <i>TLR</i> | Toll-like receptor |
| <i>TMJ</i> | $The\ temperature for the anti-decomposition of the composition of th$ |
| <i>TNF</i> | Tumor necrosis factor |
| <i>TS</i> | Total score |
| tsDMARDs | Targeted synthetic Disease modifying |
| | antirheumatic drugs |
| TST | Tuberculin skin test |
| US | |
| VAS | Visual analogue scale |
| VEGF | Vascular endothelial growth factor |
| WBCs | |